Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -22.75% is 96% above its 3-year average of -517.63%, near the high end of its 3-year range (-34005.37%–-8.22%).
6.10% below its 12-month average of -21.44%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -24.79%.
EBITDA MARGIN
-22.75%
EBITDA MARGIN AVG TTM
-21.44%
EBITDA MARGIN AVG 3Y
-115.05%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-6.10%
CURRENT VS 3Y AVG
+80.23%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
QT Imaging Holdings, Inc.
Market Cap
$35.52M
EBITDA Margin
-22.75%
TTM Avg
-21.44%
3Y Avg
-115.05%
5Y Avg
N/A
Market Cap
$35.84M
EBITDA Margin
-1929.22%
TTM Avg
-1308.49%
3Y Avg
-1783.80%
5Y Avg
-1343.37%
Market Cap
$35.84M
EBITDA Margin
-136.01%
TTM Avg
-1016.71%
3Y Avg
-1237.80%
5Y Avg
-1237.80%
Market Cap
$36.21M
EBITDA Margin
-29.82%
TTM Avg
-228.84%
3Y Avg
-176.67%
5Y Avg
-120.12%
Market Cap
$34.35M
EBITDA Margin
-127.12%
TTM Avg
-129.61%
3Y Avg
-125.08%
5Y Avg
-93.97%
Market Cap
$33.63M
EBITDA Margin
-884.81%
TTM Avg
-512.51%
3Y Avg
-340.78%
5Y Avg
-266.52%
Market Cap
$33.61M
EBITDA Margin
-7905.63%
TTM Avg
-7905.63%
3Y Avg
-7905.63%
5Y Avg
-7905.63%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| QT Imaging Holdings, Inc. (QTI) | $35.52M | -22.75% | -21.44% | -115.05% | N/A |
| DocGo Inc. (DCGO)vs › | $35.76M | -22.81% | -7.79% | -0.80% | -0.97% |
| Edesa Biotech, Inc. (EDSA)vs › | $35.84M | -1929.22% | -1308.49% | -1783.80% | -1343.37% |
| Elicio Therapeutics, Inc. (ELTX)vs › | $35.84M | -136.01% | -1016.71% | -1237.80% | -1237.80% |
| BriaCell Therapeutics Corp. (BCTX)vs › | $34.97M | N/A | N/A | N/A | N/A |
| EUDA Health Holdings Limited (EUDA)vs › | $36.21M | -29.82% | -228.84% | -176.67% | -120.12% |
| Elutia Inc (ELUT)vs › | $34.35M | -127.12% | -129.61% | -125.08% | -93.97% |
| Scilex Holding Company (SCLX)vs › | $33.63M | -884.81% | -512.51% | -340.78% | -266.52% |
| Grace Therapeutics, Inc. (GRCE)vs › | $33.61M | -7905.63% | -7905.63% | -7905.63% | -7905.63% |
| Aligos Therapeutics, Inc. (ALGS)vs › | $33.29M | -3982.39% | -3087.93% | -1849.71% | -2051.20% |
Gross Margin
39.6%
EBITDA Margin
-22.8%
Operating Margin
-17.4%
Net Margin
-65.3%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -24.79% |
| 2026-03-31 | -8.22% |
| 2025-12-31 | -8.27% |
| 2025-09-30 | -38.47% |
| 2025-06-30 | -27.46% |
| 2025-03-31 | -35.88% |
| 2024-12-31 | -239.17% |
| 2024-09-30 | -241.40% |
| 2024-06-30 | -124.51% |
| 2024-03-31 | -402.29% |
| 2023-12-31 | -13911.55% |
| 2023-09-30 | -4543.43% |
| 2023-06-30 | -34005.37% |
| 2023-03-31 | -21626.64% |
